Important insights into the mechanisms behind Fuchs Endothelial Corneal Dystrophy (FECD), a common cause of age-related visual loss, have been revealed in a new study led by UCL researchers. The study ...
GenEditBio has dosed the first subject in an investigator-initiated trial of its in vivo genome editing programme, GEB-101, for transforming growth factor beta induced (TGFBI) corneal dystrophy. The ...
The National Institutes of Health has renewed its funding of eye disease research led by Mark D. Parker, PhD, associate professor of physiology and biophysics. The National Eye Institute is funding a ...
Bayer’s BAYRY wholly owned subsidiary, BlueRock Therapeutics, announced that the first patient in the phase I/IIa CLARICO study has received OpCT-001, an investigational iPSC-derived cell therapy, ...
Ocugen says it is on track to reshape the market for gene therapies against eye disorders over the next three years, by working to bring to market three treatments for blindness-related diseases, two ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback